Try our Advanced Search for more refined results

Mitchell et al v. AbbVie, Inc. et al

  1. April 24, 2018

    AbbVie Disputes $3M AndroGel Verdict In MDL Bellwether

    AbbVie Inc. asked an Illinois federal court Monday to grant a new trial, enter a judgment against the patient who brought suit or overturn a $3.2 million verdict that found the drugmaker's testosterone replacement therapy AndroGel caused the patient's heart attack, saying the jury's finding was contradictory.

  2. March 26, 2018

    AbbVie Ordered To Pay $3M In AndroGel Retrial

    An Illinois federal jury on Monday found AbbVie Inc.'s AndroGel product caused an Oregon man's heart attack and ordered the company to pay him more than $3 million, a verdict that came in the latest bellwether trial in the multidistrict litigation over testosterone replacement therapy drugs.

  3. March 22, 2018

    AbbVie Must Be Sent Message, Jury Told In AndroGel Trial

    Attorneys for a man who suffered a heart attack while on AbbVie's AndroGel wrapped up their case Thursday, telling an Illinois federal jury that the pharmaceutical company won't change the way it sells its blockbuster testosterone replacement therapy drug unless it is sent a strong message and faces financial pressure.

  4. March 07, 2018

    Retrial Begins In Original Testosterone MDL Bellwether

    Attorneys for a man who had a heart attack while taking AbbVie Inc.'s testosterone replacement therapy product AndroGel opened the retrial of the man's claims against the pharmaceutical company Wednesday, telling an Illinois federal jury AbbVie didn't tell his doctor about the drug's risks.

  5. February 26, 2018

    Judge Orders Redo In First AbbVie Testosterone MDL Trial

    An Illinois federal judge has ordered a new trial in the first bellwether against AbbVie Inc. in the multidistrict litigation over testosterone replacement therapy products after finding that the jury likely misunderstood the issue of causation.

  6. October 26, 2017

    Defeated AndroGel User Must Pay Own Bills, AbbVie Says

    An Illinois federal jury was right to deny an Androgel user money to cover his medical bills after it found the AbbVie Inc. drug didn't cause his heart attack, even though the same jury found the company was on the hook for $150 million in punitive damages tied to false advertising, AbbVie told the court Wednesday.

  7. August 22, 2017

    AbbVie, Patient Both Say Jury On Their Side In $150M Award

    AbbVie Inc. and an AndroGel user who claimed the product caused his heart attack attempted to salvage their unusual jury verdict Monday, with both sides telling an Illinois federal judge the panel's $150 million award sent a clear message in their favor.

  8. August 03, 2017

    Hurdles Ahead For AbbVie After $150M AndroGel Verdict

    An Illinois federal jury may have cleared AbbVie of causing an AndroGel user's heart attack, but its award of $150 million in punitive damages against the drugmaker for misleading advertising saddles AbbVie with clear challenges in future trials in multidistrict litigation, attorneys say.

  9. July 24, 2017

    AbbVie Must Pay $150M For False AndroGel Ads, Jury Says

    An Illinois federal jury on Monday found that AbbVie Inc. isn't liable for an AndroGel user's heart attack but ordered the company to pay $150 million in punitive damages for funding ads that misrepresented what the testosterone replacement therapy drug could treat.

  10. July 21, 2017

    Jury Begins Deliberations In Suit Over AbbVie's AndroGel

    A man who claims he had a heart attack after using AbbVie Inc.'s testosterone replacement therapy drug AndroGel made his final plea to the Illinois federal jury hearing his case Friday, saying every decision the company made about the product had "consequences for real people."